secwatch.observer — SEC 8-K summary
======================================

Issuer:     Savara Inc (SVRA)
CIK:        0001160308
Form:       8-K
Filed at:   2025-05-27T23:59:59+00:00
Accession:  0001193125-25-126273
Event type: regulatory
Sentiment:  negative
Materiality: 0.85
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Savara receives FDA Refusal to File for MOLBREEVI BLA; resubmission expected Q4 2025
--------------------------------------------------------------------------------

- FDA requested additional CMC data; RTF not due to safety or efficacy concerns.
- Company plans Type A meeting within 30 days to align on next steps.
- BLA for autoimmune PAP was submitted March 2025; resubmission targeted for Q4 2025.
- Technology transfer for second-source drug substance manufacturer on track; three PPQ batches completed.
- MOLBREEVI retains Fast Track, Breakthrough Therapy, and Orphan Drug status.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1160308/000119312525126273/0001193125-25-126273-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1160308/000119312525126273/d845572d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-126273

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer